Antigenics CEO Receives Humanitarian Award from the Sabin Vaccine Institute
6/29/2006 7:00:00 AM EST
Genetic Engineering News
BIOWIRE
Antigenics Inc. (NASDAQ: AGEN) today announced that the Sabin Vaccine Institute has awarded the company's chairman and CEO, Garo H. Armen, PhD, the 2006 Sabin Humanitarian Award. The Albert B. Sabin Annual Awards recognize extraordinary figures in biotechnology, medical research and medical reporting, and were celebrated at a gala, themed "Celebrating Hope for a Healthier World," in New York City last night.
"In each case, these extraordinary individuals didn't settle for high achievement in just one area, but they broadened their horizons and multiplied their effect," said H. R. Shepherd, DSc, chairman of the Sabin Vaccine Institute. "They each found new ways to further medical science, reaching out to help a greater cross-section of humanity."
Dr. Armen cofounded Antigenics in 1994 with Pramod K. Srivastava, PhD. Dr. Armen is also the founder and chairman of the Children of Armenia Fund, a charitable organization established in 2000 that is dedicated to the positive development of the children and youth of Armenia. From mid-2002 through 2004, Dr. Armen also served as chairman of the board of directors of the pharmaceutical company Elan Corporation. He received a PhD in physical chemistry from the Graduate Center, City University of New York.
About the Albert B. Sabin Vaccine Institute
The Albert B. Sabin Vaccine Institute is a public, nonprofit organization dedicated to continuing the work of Dr. Albert Sabin, who envisioned the enormous potential of vaccines to prevent deadly disease. The Sabin Vaccine Institute (SVI) promotes rapid scientific advances in vaccine development, delivery and distribution worldwide. SVI's Cancer Vaccine Consortium provides a mechanism for collaborative activity to speed the research, regulatory process and delivery of new cancer vaccines to the market.
The SVI grants annual Sabin Awards to honor individuals for their extraordinary and ongoing contributions, and generosity of spirit inspiring humanitarian actions. Their personal life and public work exemplify the best of human kindness, and their continuous efforts to alleviate suffering inspire hope for the greater good of all.
About Antigenics
Antigenics is a biotechnology company working to develop treatments for cancers, infectious diseases and autoimmune disorders. For more information, please visit www.antigenics.com.
CONTACT:
Antigenics Inc. Media Relations: Sunny Uberoi, 212-994-8206 suberoi@antigenics.com Investor Relations: Shalini Sharp, 800-962-2436 ir@antigenics.com
Note: Above are excerpts from the article. The full article appears here. Clarifications and comments by me are contained in {}. Deletions are marked by [...]. The bold emphasis is mine.
Genetic Engineering News
BIOWIRE
Antigenics Inc. (NASDAQ: AGEN) today announced that the Sabin Vaccine Institute has awarded the company's chairman and CEO, Garo H. Armen, PhD, the 2006 Sabin Humanitarian Award. The Albert B. Sabin Annual Awards recognize extraordinary figures in biotechnology, medical research and medical reporting, and were celebrated at a gala, themed "Celebrating Hope for a Healthier World," in New York City last night.
"In each case, these extraordinary individuals didn't settle for high achievement in just one area, but they broadened their horizons and multiplied their effect," said H. R. Shepherd, DSc, chairman of the Sabin Vaccine Institute. "They each found new ways to further medical science, reaching out to help a greater cross-section of humanity."
Dr. Armen cofounded Antigenics in 1994 with Pramod K. Srivastava, PhD. Dr. Armen is also the founder and chairman of the Children of Armenia Fund, a charitable organization established in 2000 that is dedicated to the positive development of the children and youth of Armenia. From mid-2002 through 2004, Dr. Armen also served as chairman of the board of directors of the pharmaceutical company Elan Corporation. He received a PhD in physical chemistry from the Graduate Center, City University of New York.
About the Albert B. Sabin Vaccine Institute
The Albert B. Sabin Vaccine Institute is a public, nonprofit organization dedicated to continuing the work of Dr. Albert Sabin, who envisioned the enormous potential of vaccines to prevent deadly disease. The Sabin Vaccine Institute (SVI) promotes rapid scientific advances in vaccine development, delivery and distribution worldwide. SVI's Cancer Vaccine Consortium provides a mechanism for collaborative activity to speed the research, regulatory process and delivery of new cancer vaccines to the market.
The SVI grants annual Sabin Awards to honor individuals for their extraordinary and ongoing contributions, and generosity of spirit inspiring humanitarian actions. Their personal life and public work exemplify the best of human kindness, and their continuous efforts to alleviate suffering inspire hope for the greater good of all.
About Antigenics
Antigenics is a biotechnology company working to develop treatments for cancers, infectious diseases and autoimmune disorders. For more information, please visit www.antigenics.com.
CONTACT:
Antigenics Inc. Media Relations: Sunny Uberoi, 212-994-8206 suberoi@antigenics.com Investor Relations: Shalini Sharp, 800-962-2436 ir@antigenics.com
Note: Above are excerpts from the article. The full article appears here. Clarifications and comments by me are contained in {}. Deletions are marked by [...]. The bold emphasis is mine.
posted by Vahe Balabanian at 8:04 AM
0 Comments:
Post a Comment
<< Home